Canton Strategic Holdings (CNTN) Liabilities and Shareholders Equity (2020 - 2026)
Canton Strategic Holdings posted quarterly Liabilities and Shareholders Equity of $584.7 million for Q1 2026, up 35092.72% year-on-year from N/an in Q1 2025, and up 12.62% on a QoQ basis from $519.1 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $584.7 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 35092.72% year-over-year to $584.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 5796.96% YoY), and the FY2025 full-year result was $519.1 million, up 13849.46% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $584.7 million, up from $519.1 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $584.7 million in Q1 2026 and bottomed at $1.7 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $7.7 million (2025), against an average of $70.7 million.
- The widest annual swing landed in 2025, when Liabilities and Shareholders Equity slumped 81.31%; it then soared 35092.72% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $6.7 million in 2022, then soared by 63.66% to $10.9 million in 2023, then tumbled by 66.0% to $3.7 million in 2024, then surged by 13849.46% to $519.1 million in 2025, then climbed by 12.62% to $584.7 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $584.7 million (Q1 2026), $519.1 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | 584.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 584.65 Mn |
| Dec 31, 2025 | 519.15 Mn |
| Sep 30, 2025 | 7.70 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 3.72 Mn |
| Sep 30, 2024 | 5.25 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Mar 31, 2024 | 8.89 Mn |
| Dec 31, 2023 | 10.95 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 4.60 Mn |
| Mar 31, 2023 | 4.72 Mn |
| Dec 31, 2022 | 6.69 Mn |
| Sep 30, 2022 | 8.02 Mn |
| Jun 30, 2022 | 10.25 Mn |
| Mar 31, 2022 | 12.09 Mn |
| Dec 31, 2021 | 621,677.00 |
| Dec 31, 2020 | 294,798.00 |